Carbonic anhydrase IX (CAIX), a genetic product downstream of the hyperactivation of the hypoxia inducible factor (HIF) pathway, is an interesting therapeutic target, being present with greater density in patients with ccRCC. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.